The net effect of disrupting PAR chain dynamics, favoring either synthesis or degradation, will likely depend on the DNA replication and repair vulnerabilities present in any given tumor cell. Thus, while PARG inhibitors may open up opportunities to treat PARP-inhibitor-resistant ovarian cancers, maximizing this opportunity will require robust, mechanism-derived predictive biomarkers. This evidence concerns the gene PARG and ovarian carcinoma.